

# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 19 Sep 2022 (#37)

[Click on blue hyperlink for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit <a href="www.grants.nih.gov">www.grants.nih.gov</a> or <a href="www.sun.ac.za/RDSfunding">www.grants.nih.gov</a> or <a href="www.sun.ac.za/RDSfunding">www.sun.ac.za/RDSfunding</a> (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: <u>cdevries@sun.ac.za</u> ● Stellenbosch Campus <u>lizelk@sun.ac.za</u>

## To prepare an application can take 4-18 months, depending on many factors:

- 1. Mechanism for which you will apply e.g. U54, R01, D43, K43
- 2. Requirement of preliminary data
- 3. Time to assemble the research team
- 4. Time available to work on the grant, taking into consideration other responsibilities
- 5. Time for internal review

#### **Parent Announcements**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- <u>PA-20-196</u> NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

#### **Important Notices**

NOT-OD-22-210 Financial Conflict of Interest (FCOI) and Other Support: Reminders. The purpose of this Guide Notice is two fold: (1) to remind the NIH extramural research community about the longstanding requirements provided in the financial conflict of interest (FCOI) regulation at 42 CFR Part 50 Subpart F, "Promoting Objectivity in Research" (FCOI regulation for grants and cooperative agreements). This requirement also is included in the NIH Grants Policy Statement (NIH GPS), Section 4.1.10, Financial Conflict of Interest, and serves as a term and condition of NIH grant awards. This Notice reminds the extramural applicants and recipient institutions of the requirements to develop a FCOI policy, to post it on their website and submit it to NIH, to ensure Investigator disclosure of both foreign and domestic Significant Financial Interests(SFI), to review Investigator SFIs, to determine if there is a FCOI that must be reported to NIH, and to train Investigators on FCOI requirements; and (2) to remind the NIH extramural research community of the requirement to submit complete and accurate Other Support information (NOT-OD-21-073) (NOT-OD-21-110).

NOT-TW-22-006 Notice of Intent to Publish a Funding Opportunity Announcement for Implementation Research on Non-Communicable Disease (NCD) Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments. The National Institutes of Health (NIH), in collaboration with the Global Alliance for Chronic Diseases (GACD), intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for implementation research addressing risk factors for common noncommunicable diseases (NCDs) in low- and middleincome countries (LMICs) and American Indian/Alaska Native (AI/AN) populations in the United States (US). Chronic NCDs, such as diabetes, cardiovascular disease, neurological disorders and stroke, respiratory diseases, certain cancers, and mental health disorders are the leading cause of morbidity and mortality in both LMICs and high-income countries (HICs), especially within AI/AN populations in the United States. The COVID-19 pandemic has brought NCDs further into the spotlight, as the majority of those who have experienced severe illness and death have had one or more underlying NCDs. Reducing the burden of NCDs is therefore critical to building more resilient, equitable, and healthier societies. NIH partners plan to publish FOAs with the R01 (Clinical Trial Optional) and R61/R33 (Clinical Trial Required) activity codes in Fall 2022 with expected application due dates in Winter/Spring 2023. Historically, the following NIH ICs have participated in GACD-associated FOAs and are anticipated to continue this participation: National Cancer Institute (NCI); National Eye Institute (NEI); National Heart, Lung, and Blood Institute (NHLBI); National Institute on Aging (NIA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Environmental Health Sciences (NIEHS); National Institute of Mental Health (NIMH); National Institute on Minority Health and Health Disparities (NIMHD); and National Institute of Neurological Disorders and Stroke (NINDS).

# **Notices of Special Interest (NOSI)**

NOT-AG-22-030 Small Research Grants for Innovations in Healthy Longevity Research. This Notice of Special Interest (NOSI) invites applications for small research grants that align with the goals of the National Academy of Medicine's Healthy Longevity Grand Challenge, as well as the National Institute on Aging's (NIA) interests in supporting research to promote a long healthspan and functional independence in both aging and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This notice applies to due dates on or after February 16, 2023 and subsequent receipt dates through May 8, 2023. Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissues of the announcement through the expiration date of this notice.

• PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

NOT-HL-22-043 Basic and Translational Research on Circadian Regulation of Heart, Lung, Blood, and Sleep Disorders (R01) Circadian rhythms are driven by an internal biological clock that anticipates day/night cycles to optimize the physiology and behavior of organisms. These 24-hour patterns set our clocks for specific times of eating and sleeping, as well as optimal times for many other basic functions. Circadian regulation of gene expression and cellular function has been reported in nearly all tissues that have been implicated in the pathogenesis of heart, lung, blood and sleep diseases. Circadian rhythm misalignment, resulting from irregular or insufficient sleep schedules, biologically inappropriate light exposure, and diet-associated zeitgebers pose an emerging risk to health world-wide. In the U.S., 30-40% of adults and 40-70% of adolescents report symptoms of poor circadian and sleep health annually. Additionally, circadian variations result in the increased frequency of heart attacks and arrhythmia, the severity of ischemic myocardial injury and bronchial responsiveness, and levels of inflammation factors have been observed, but the underlying molecular mechanisms are not clearly understood. This notice applies to due dates on or after January 25, 2023 and subsequent receipt dates through January 7, 2028.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

- PA-20-183 NIH Research Project Grant (Parent R01 Clinical Trial Required) (Mechanistic trials only)
- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

**NOTE:** NHLBI will accept applications to <u>PA-20-183</u> - NIH Research Project Grant (Parent R01 Clinical Trial Required) if they propose mechanistic studies that meet <u>NIH's definition of a clinical trial</u> and that have the primary goal of understanding how an intervention works per guidance in <u>NOT-HL-19-690</u>. Applicants are *strongly* encouraged to consult the NHLBI Scientific/Research Contact listed below prior to submission to confirm the NHLBI-specific clinical trial FOA to which the application should be submitted.

### **Funding Opportunity Announcements (FOA)**

1. Limited Competition: The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) (U24 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: RFA-HG-22-020

Type: U24

**Application Due Date:** December 02, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this FOA is to solicit applications for development, maintenance, and user support for the NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL). AnVIL is a scalable and interoperable resource for the basic and clinical genomic research communities that leverages a cloud-based infrastructure to democratize data access, sharing, and computing across large genomic and genomic-related datasets. This is a limited competition RFA. Only recipient organizations funded

under RFA-HG-17-011 are eligible to apply.

**Budget**: NHGRI intends to commit a total of \$6,500,000 per year in FY 2023 through FY 2027 to fund up to 2 awards. This is a limited competition RFA. Only recipient organizations funded under <u>RFA-HG-17-011</u> are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space Clinical Resource (ACR) (U24 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: RFA-HG-22-021

Type: U24

**Application Due Date:** December 02, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support the development, implementation, and maintenance of the AnVIL Clinical Resource (ACR), a suite of genomic-based clinical tools and services built into the NHGRI Data Science Analysis, Visualization, and Informatics Lab-Space (AnVIL) to foster clinical genomic research. AnVIL is a scalable and interoperable resource for the basic and clinical genomic research communities that leverages a cloud-based infrastructure to democratize data access, sharing, and computing across large genomic and genomic-related datasets.

**Budget**: NHGRI intends to commit a total of \$1,500,000 per year in FY 2023 through FY 2027 to fund 1 award. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Enquiries: *Christa*e: <u>cdevries@sun.ac.za</u> | t: +27 21 938 9838

Enquiries: *Lizél* e: <u>lizelk@sun.ac.za</u> | t: +27 21 808 2105